BCD-256
/ Biocad
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
August 23, 2025
Safety, Pharmacokinetics, Immunogenicity BCD-256-1 and Divozilimab in Subjects With Systemic Lupus Erythematosus
(clinicaltrials.gov)
- P1 | N=135 | Recruiting | Sponsor: Biocad
Monotherapy • New P1 trial • Immunology • Inflammatory Arthritis • Lupus • Systemic Lupus Erythematosus
1 to 1
Of
1
Go to page
1